Breaking News Instant updates and real-time market news.

KNSA

Kiniksa

$26.47

1.62 (6.52%)

09:04
09/15/18
09/15
09:04
09/15/18
09:04

Kiniksa presents Phase 1a/1b data for KPL-716 in atopic dermatitis

Kiniksa Pharmaceuticals presented Phase 1a/1b clinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta, at the 27th European Academy of Dermatology and Venereology Congress. In this First-in-Human clinical trial, single intravenous and subcutaneous doses of KPL-716 were well-tolerated in both adult healthy volunteers and adult subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus, the company said. KPL-716 also demonstrated a reduction in pruritus, it added. "The results support Kiniksa's plans for expanding clinical development into multiple chronic pruritic diseases, including prurigo nodularis," said the company. In total, 50 healthy volunteers and 32 subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus received a single dose of KPL-716 or placebo in the Phase 1a/1b clinical trial, with the top dose of 20 mg/kg IV in healthy volunteers and 7.5 mg/kg IV in subjects with atopic dermatitis. The mean percentage change in weekly-average Worst-Itch Numeric Rating Scale decreased by 40.4% in KPL-716 recipients compared to a 17.6% decrease in placebo recipients at Day 28 in the absence of concomitant TCS. The mean percentage change in Pruritus Visual Analog Scale decreased by 55.4% in KPL-716 recipients compared to a 10.4% decrease in placebo recipients at Day 28 in the absence of concomitant TCS. "The KPL-716 Phase 1a/1b results met a high hurdle for success, as the placebo-controlled, single-dose safety and pharmacokinetics study also demonstrated reduction in pruritus," said John F. Paolini, MD, PhD, Chief Medical Officer of Kiniksa. "We are now considering advancement of KPL-716 into multiple chronic pruritic diseases, including prurigo nodularis. Additionally, the observed reduction in EASI scores after only a single dose of KPL-716 is encouraging. Our ongoing repeat-single-dose trial in atopic dermatitis subjects will provide longer-term exposures and data on these inflammatory disease response markers."

  • 03

    Oct

  • 11

    Oct

KNSA Kiniksa
$26.47

1.62 (6.52%)

06/18/18
GSCO
06/18/18
INITIATION
Target $22
GSCO
Neutral
Kiniksa initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Kiniksa Pharmaceuticals with a Neutral rating and $22 price target. The analyst is encouraged by the company's autoimmune focus and a number of near-term catalysts, but he views the current valuation as fair.
06/18/18
JPMS
06/18/18
INITIATION
Target $29
JPMS
Overweight
Kiniksa initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Kiniksa with an Overweight rating and $29 price target. The company has an emerging mid-stage auto-inflammation / auto-immune pipeline with multiple potential value creation catalysts over the next 6-24 months, Rama tells investors in a research note. He believes Kiniksa's pipeline is de-risked with "strong scientific rationale."
06/18/18
WEDB
06/18/18
INITIATION
Target $31
WEDB
Outperform
Kiniksa initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten started Kiniksa with an Outperform rating and $31 price target as he believes shares are undervalued given the company's initial focus on late-stage, clinically de-risked assets for rare diseases with limited competition, as is the case for rilonacept in recurrent pericarditis and mavrilimumab in giant cell arteritis.
06/18/18
JMPS
06/18/18
INITIATION
Target $33
JMPS
Outperform
Kiniksa initiated with an Outperform at JMP Securities
Before the open, JMP Securities analyst Liisa Bayko started coverage of Kiniksa with an Outperform rating and $33 price target, stating that the company has put together a clinical-stage portfolio of three unique medicines that are "well spaced at different stages of development" in an "impressively short period of time."

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
09/20/18
09/20
12:17
09/20/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCI

Rogers Communications

$52.08

0.41 (0.79%)

12:17
09/20/18
09/20
12:17
09/20/18
12:17
Hot Stocks
Rogers, UBC sign multi-year agreement to build 5G hub in Vancouver »

Rogers and the University…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
09/20/18
09/20
12:16
09/20/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBT

BB&T

$51.56

0.59 (1.16%)

12:10
09/20/18
09/20
12:10
09/20/18
12:10
Conference/Events
BB&T management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 18

    Oct

GE

General Electric

$12.45

-0.415 (-3.23%)

, UAA

Under Armour

$19.93

1.175 (6.27%)

12:09
09/20/18
09/20
12:09
09/20/18
12:09
General news
Fly Intel: Wall Street's top stories at midday »

Stocks opened in positive…

GE

General Electric

$12.45

-0.415 (-3.23%)

UAA

Under Armour

$19.93

1.175 (6.27%)

DIS

Disney

$111.69

1.81 (1.65%)

FOXA

21st Century Fox

$44.71

0.11 (0.25%)

CMCSA

Comcast

$37.54

0.22 (0.59%)

CRBP

Corbus Pharmaceuticals

$6.90

1.75 (33.98%)

FOLD

Amicus

$12.72

0.92 (7.80%)

SFIX

Stitch Fix

$41.40

-5.81 (-12.31%)

THO

Thor Industries

$92.25

-13.47 (-12.74%)

RHT

Red Hat

$134.22

-9.16 (-6.39%)

FOX

21st Century Fox

$44.34

0.09 (0.20%)

CMCSK

Comcast

$0.00

(0.00%)

UA

Under Armour

$18.29

1.01 (5.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 01

    Oct

  • 27

    Nov

NSANY

Nissan

$0.00

(0.00%)

12:07
09/20/18
09/20
12:07
09/20/18
12:07
Hot Stocks
Nissan recalls over 215,000 vehicles in U.S. for antilock brake pump defect »

Nissan North America is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:05
09/20/18
09/20
12:05
09/20/18
12:05
General news
Libor has been moving higher »

Libor has been moving…

SKY

Skyline

$28.20

-2.405 (-7.86%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Hot Stocks
Skyline falls -7.9% »

Skyline is down -7.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

SSW

Seaspan

$8.05

-1.105 (-12.08%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Hot Stocks
Seaspan falls -12.2% »

Seaspan is down -12.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THO

Thor Industries

$92.17

-13.55 (-12.82%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Hot Stocks
Thor Industries falls -12.8% »

Thor Industries is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTL

Mechel

$3.29

0.335 (11.34%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Hot Stocks
Mechel rises 12.8% »

Mechel is up 12.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEW

Puxin Limited

$8.51

0.94 (12.42%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Hot Stocks
Puxin Limited rises 13.2% »

Puxin Limited is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNST

Monster Beverage

$60.26

0.95 (1.60%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Options
Monster Beverage option volume is 3X daily average and calls lead puts 10:1 »

Monster Beverage option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COE

China Online Education

$7.00

(0.00%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Hot Stocks
China Online Education rises 15.9% »

China Online Education is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPOA

Social Capital

$9.88

-0.05 (-0.50%)

11:55
09/20/18
09/20
11:55
09/20/18
11:55
Hot Stocks
Social Capital's Palihapitiya says no longer accepting new outside capital »

In a Medium post entitled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
09/20/18
09/20
11:55
09/20/18
11:55
Conference/Events
William Blair business services analyst holds group luncheon »

Business Services Analyst…

11:55
09/20/18
09/20
11:55
09/20/18
11:55
Conference/Events
Stephens specialty finance analyst to hold a group luncheon »

Specialty Finance Analyst…

MGTI

MGT Capital Investments

$0.00

(0.00%)

11:52
09/20/18
09/20
11:52
09/20/18
11:52
Hot Stocks
MGT Capital Investments announces partnership with MMH Blockchain »

MGT Capital Investments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXTA

Axalta Coating

$30.16

0.23 (0.77%)

11:50
09/20/18
09/20
11:50
09/20/18
11:50
Options
Axalta Coating Systems attracts bullish option spreads »

Axalta Coating Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EAF

GrafTech

$20.10

1.015 (5.32%)

11:49
09/20/18
09/20
11:49
09/20/18
11:49
Recommendations
GrafTech analyst commentary  »

GrafTech selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

11:45
09/20/18
09/20
11:45
09/20/18
11:45
Options
Tandem Diabetes call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 27

    Nov

BYSI

BeyondSpring

$25.55

(0.00%)

11:44
09/20/18
09/20
11:44
09/20/18
11:44
Conference/Events
BeyondSpring management to meet with RBC Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

11:43
09/20/18
09/20
11:43
09/20/18
11:43
Conference/Events
RBC Capital healthcare tech analyst to hold analyst/industry conference call »

Healthcare Technology…

EB

Eventbrite

$0.00

(0.00%)

11:36
09/20/18
09/20
11:36
09/20/18
11:36
Syndicate
Breaking Syndicate news story on Eventbrite »

Eventbrite opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

DNR

Denbury Resources

$5.49

-0.095 (-1.70%)

11:35
09/20/18
09/20
11:35
09/20/18
11:35
Options
Denbury Resources put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.